LSPN954

LSPN954 (compound 4i) (0.049-50 μM; 72 h for P. falciparum; 1.56-100 μM; 72 h for HepG2) potently inhibits Plasmodium falciparum 3D7 growth with an IC₅₀ of 1.7 μM, shows low cytotoxicity against human HepG2 and HEK293 cells, and has high selectivity indices of 59 and >59, respectively^[1].
LSPN954 (0.049-50 μM; 24, 48, 72 h exposure periods; 10× IC₅₀; 24 h morphological analysis) exhibits slow-acting inhibitory activity against Plasmodium falciparum 3D7, as shown by IC₅₀ ratios above 1 for 24 h vs 72 h exposure and a 4-fold ratio for 6-day vs 4-day regrowth, plus morphological evidence of parasite recovery after initial exposure^[1].
LSPN954 (0.01-100 μM; 72 h, with 200 μM IPP co-treatment) antiplasmodial activity against Plasmodium falciparum 3D7 is not reversed by IPP supplementation, indicating its activity does not involve inhibition of apicoplast-dependent isoprenoid biosynthesis^[1].
LSPN954 (0.049-50 μM; 72 h) retains potent antiplasmodial activity against multidrug-resistant Plasmodium falciparum strains (3D7R_MMV848, Dd2R_DSM265, Dd2, K1, TM90C6B) with resistance indices close to 1, indicating no cross-resistance with standard antimalarials^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.